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Abstract The p53 core DNA binding domain has been implied
in Mdm2-mediated protein degradation. Here we show that the
substitution of the serine residues 116 and 127 with alanine
residues (S116/127A) has no e¡ect on p53 DNA binding and
protein stability. However, the substitution of the serine residues
with the aspartic acid (S116/127D) abolished p53 DNA binding
and led to protein stabilization. Importantly, we have shown
that S116/127D exhibits a structural mutant conformation that
results in a loss of p53-dependent transcription and Mdm2-
mediated protein degradation.
- 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Wild-type p53 exerts its tumor suppression activity by bind-
ing to speci¢c DNA sequences and functioning as a transcrip-
tion factor [1]. The wild-type p53 protein is maintained at low
levels in most cells because of the short p53 protein half-life
[2]. In contrast, the p53 protein accumulates dramatically in
response to various cellular stresses that include DNA damage
[3]. The cellular protein Mdm2 functions as a major negative
regulator of p53 by acting as a ubiquitin E3 ligase, promoting
p53 ubiquitination and subsequent degradation [4]. Con-
versely, Mdm2 is also a transcriptional target of p53 and
the expression of Mdm2 is activated by p53 at the transcrip-
tion level [5,6]. This allows the formation of a unique autor-
egulatory feedback loop in restraining the p53 protein levels
and activity. The physiological relationship between p53 and
Mdm2 is further supported by Mdm2 gene knockout studies
in mice. Disruption of the murine Mdm2 locus results in early
embryonic death, which can be rescued by the further inacti-
vation of p53 [7,8]. Mutation of p53 therefore results in the
loss of DNA binding required for Mdm2 activation and sub-
sequent protein stabilization.
The p53 protein can be divided functionally and structur-
ally into ¢ve regions: the acidic N-terminal transactivation
domain, the proline-rich stretch, the hydrophobic core DNA
binding domain which bears 95% of 10 000 somatic tumori-
genic TP53 mutations [9], the oligomerization domain, and
the C-terminal domain [10]. In addition to having a role in
DNA binding, the N-terminal region of the core domain has
been implied in Mdm2-mediated protein degradation. Muta-
tion of the COP9 signalosome (CSN) phosphorylation site
(Thr155) to valine (T155V) results in p53 stabilization [11].
The amino acid residues 92^112 of p53 have been suggested
to inhibit p53 by acting as a signal for Mdm2-mediated pro-
tein degradation [12]. Results from our laboratory have also
revealed a potential inhibitory domain between amino acids
92 and 109 (Abela and Liu, unpublished results). Of note, the
c-jun protein also contains an inhibitory domain capable of
silencing its activation function. Furthermore, the c-jun inhib-
itory domain has been shown to interact with the c-jun N-ter-
minal kinase (JNK). JNK is a member of the mitogenic acti-
vated protein kinase (MAPK) family, which can regulate c-jun
protein levels through phosphorylation of serine residues 63
and 73. A comparison of the regulatory region of c-jun has
revealed its homology with a p53 inhibitory domain, partic-
ularly with two serine residues at positions 116 and 127 (Fig.
1B), which prompted us to examine the function of the two
serines in p53 DNA binding and protein degradation.
Here, we show that the substitution of the serine residues
with the alanine (S116/127A) has no e¡ect on p53 DNA bind-
ing and protein stability. However, the substitution of the
serine with the aspartic acid residues (S116/127D) abolished
p53 DNA binding and led to p53 stabilization. Importantly,
we have shown that the S116/127D mutant exhibits a struc-
tural mutant conformation that can be recognized by anti-
mutant p53 but not anti-wild-type p53 antibody. Further-
more, the S116/127D mutant can be degraded by overexpres-
sion of Mdm2. These results suggest that the serine residues
116 and 127 are important for p53 DNA binding, and the
substitution of the serine residues with aspartic acid leads to
a loss of p53-dependent transcription and Mdm2-mediated
protein degradation.
2. Materials and methods
2.1. Plasmid
p53 S116/127A and S116/127D were generated by polymerase chain
reaction (PCR) using pcDNA-p53 as a template and con¢rmed by
sequencing analysis. The luciferase reporter plasmid pRGCE4luc
was as described [13].
2.2. Transfection, luciferase and Western blot analysis
Various combinations of plasmids were transfected into Saos2 cells
by use of the calcium phosphate method. The amounts of plasmids
used for transfection of 60 mm plates were as follow: 0.5 Wg of
pRGCE4Luc, 0.2 Wg of wild-type p53 or mutants (S116/127A, S116/
127D, R175H and R248W). Luciferase assays were normalized for
L-galactosidase activity from a cotransfected control expression vector
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as described [14]. We used Lipofectamine (Invitrogen) for transfection
in p53/Mdm2 double knockout mouse embryonic ¢broblast cells
(p533/3 ; Mdm23/3MEF). A total of 0.2 Wg of wild-type p53 or
various mutants in the presence or absence of 1.2 Wg pCMVMdm2
was used for transfection on 60 mm plates. 28^32 h posttransfection,
the cells were lysed in ‘L’ lysis bu¡er (50 mM Tris^HCl pH 8.0, 120
mM NaCl, 0.5% NP-40). The Mdm2 and p53 proteins were detected
by use of monoclonal antibodies SMP14 (anti-Mdm2) and DO1 (anti-
p53, Santa Cruz).
2.3. Electrophoretic mobility shift assay (EMSA)
pcDNA-p53 and various mutant plasmids (0.5 Wg each) were trans-
fected into Saos2 cells on 60 mm plates with use of Lipofectamine
2000 reagent (Invitrogen). 30 h posttransfection, nuclear proteins were
isolated as described [15]. In brief, cells were allowed to swell on ice in
a hypotonic bu¡er, the nuclei were then collected, and nuclear pro-
teins were extracted in a high-salt bu¡er. To minimize proteolysis, all
bu¡ers contained freshly added 0.5 mM phenylmethylsulfonyl £uoride
(PMSF), 0.5 mM dithiothreitol (DTT), 5 Wg/ml aprotinin, 5 Wg/ml
leupeptin, and 5 Wg/ml antipain. The nuclear extracts were snap-fro-
zen in liquid N2 and stored at 380‡C. The amounts of the protein
used in each EMSA were normalized to wild-type p53. EMSA was
performed as described [16]. The ribosomal gene cluster (RGC) p53
binding site probe (5P-AGCTTGCCTCGAGCTTGCCTGGACTT-
GCCTGGTCGACGC-3P) was 32P-labeled with the Klenow polymer-
ase. Binding reactions contained 60 mM KCl, 12% glycerol, 5 mM
MgCl2, 1 mM ethylenediamine tetraacetic acid (EDTA), 0.2 Wg bovine
serum albumin (BSA), 1 Wg poly(dG-dC) and 100 cpm 32P-labeled
probe. Reactions were incubated at 30‡C for 40 min and analyzed
on a 5% polyacrylamide gel electrophoresis (PAGE) gel contain-
ing 0.5Utriborate EDTA (TBE). DNA^protein complexes were visu-
alized with a phosphorimager with use of the Adobe Photoshop soft-
ware.
2.4. Immunoprecipitation
Wild-type p53 and various p53 mutants were transcribed and trans-
lated in vitro using [35S]methionine and the coupled in vitro TNT
system from Promega. The translated proteins were then pre-cleared
with protein G Sepharose and immunoprecipitated using 1 Wg p53
antibodies (Ab-5 or Ab-3, Oncogene). The 35S-labeled immunopreci-
pitates were subjected to 10% sodium dodecyl sulfate (SDS)^PAGE,
dried and exposed to X-ray ¢lm. Wild-type p53 and various p53
mutants were also expressed in p53/Mdm2 double knockout MEF
cells, immunoprecipitated and assayed on Western blotting with the
rabbit polyclonal anti-p53 antibody, FL-393 (Santa Cruz).
3. Results and discussion
3.1. Role of Ser116 and 127 in p53-dependent transcription
In order to study whether the serine residues 116 and 127
may have any e¡ect on the transcriptional function of p53, we
substituted the serine residues with either alanine (S116/127A)
or aspartic acid (S116/127D). Transient transfection assay was
performed in p53 null Saos2 cells, in which wild-type and
mutant p53 were tested for their ability to stimulate the ex-
pression of the luciferase gene under the control of a promoter
containing one p53 binding site (RGC) and the E4 TATA box
(pRGCE4Luc). The S116/127A mutation retained its ability
to activate transcription (Fig. 1D). However, the serine-to-
aspartic acid mutant, S116/127D, revealed a loss of transcrip-
tion activity compared with the wild-type p53. The p53
R175H and R248W mutants were included as controls (Fig.
1D). We performed Western blot analysis to ensure that the
mutant proteins were expressed at comparable levels to the
wild-type p53 (Fig. 1E). The S116/127D mutant, like the
R175H and R248W mutants, was expressed at higher levels.
This is consistent with the ¢nding that without p53-dependent
transcription of Mdm2, mutant p53 accumulates in high lev-
els. These results suggest that the serine residues 116 and 127
are important for p53 transcription activity.
3.2. Ser116 and 127 are important in p53 DNA binding
The fact that S116/127D is defect in p53 transcription
prompted us to examine the abilities of the mutants to bind
DNA. We performed a gel shift assay using a probe contain-
ing the p53 binding site identi¢ed in the RGC as described
[13]. The p53 mutants and the wild-type protein were ex-
Fig. 1. A: Functional domains of p53 and two serine residues,
Ser116 and 127, identi¢ed by sequence comparison with the c-jun
delta domain (B). C: Crystal structure of the p53 core domain^
DNA complex. The side chains of the six most frequently mutated
residues of p53 are purple or gold and Ser116 or 127 are red.
D: Saos2 cells were transiently transfected with the plasmid indi-
cated below. 28^32 h after transfection, the luciferase activity was
assayed after normalization with L-galactosidase. E: Transiently
transfected Saos2 cells were lysed with ‘L’ bu¡er and analyzed by
Western blotting using the anti-p53 antibody, DO1.
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pressed in Saos2 cells, from which nuclear lysates were pre-
pared. As expected, 50 ng of puri¢ed baculovirus-expressed
p53 bound to this probe and produced a retarded p53^DNA
complex (Fig. 2B, lane 2) which can be supershifted by the
addition of an anti-p53 antibody (DO1, lane 3). A slowly
migrated p53^DNA complex was also observed when wild-
type p53-transfected nuclear extracts were incubated with
the RGC probe (lane 6) and this complex was supershifted
by the addition of an anti-p53 antibody (DO1, lane 7). Results
of two control experiments demonstrated the speci¢city of p53
DNA binding. Nuclear extracts obtained from empty vector-
transfected Saos2 cells did not show a band at the p53^DNA
complex position (lanes 4 and 5). Also, the p53 DNA binding
observed in lane 6 could be competed by the addition of the
excess unlabeled wild-type but not mutant probes (lanes 8 and
9). Next, we tested the ability of the p53 mutants to bind
DNA. Similar to results for the wild-type p53, the addition
of S116/127A-transfected nuclear extracts resulted in a slowly
migrated band (Fig. 2B, lane 12) and a supershifted band
when the anti-p53 antibody DO1 was added (lane 13). In
contrast, S116/127D was signi¢cantly impaired in its ability
to bind DNA (lane 14). In these experiments, R175H and
R248W were used as negative controls, as they carry muta-
tions in the DNA binding region (lanes 15 and 16). The
amounts of protein used in each reaction are shown in Fig.
2A.
3.3. S116/127D exhibits a structural mutant (Pab240+)
conformation
Two classes of p53 mutations, ‘DNA contact’ and ‘struc-
tural’, have been described previously [9]. The contact mu-
tants preferentially bind to the Pab1620 antibody (raised
against native p53), as they have a native conformation,
whereas the structural mutants speci¢cally bind to the
Pab240 antibody (raised against denatured p53), which recog-
nizes an epitope inaccessible in the native conformation. Be-
cause the serine residues 116 and 127 positioned close to R282
(Fig. 1C), we postulated that the addition of positive charges
to these residues might contribute to the disruption of the
surrounding structure of R282 and abolished p53 DNA bind-
ing. We then examined the mutant type of S116/127D using
the Pab1620 and Pab240 antibodies. In these experiments, the
S116/127A and S116/127D mutants were either translated in
vitro or transiently expressed in vivo and immunoprecipitated
with the Pab1620 and Pab240 antibodies. As shown in Fig. 3,
S116/127A was only recognized by Pab1620 antibody, indicat-
ing it was in its native conformation state. In contrast, S116/
127D was recognized only by the Pab240 antibody, which
suggests that this mutant exhibits the structural mutant
(Pab240+) conformation. As controls, wild-type p53 and the
reported ‘DNA contact’ mutant R248W were recognized by
Pab1620 but not Pab240 antibodies, whereas the ‘structural’
mutant R175H was recognized by Pab240, but not Pab1620
antibodies. These results show that the S116/127D mutant
exhibits the structural mutant conformation and therefore is
unable to bind DNA.
 
           
Fig. 2. p53 S116/127A but not S116/127D binds to DNA. A: Saos2
cells were transiently transfected with various plasmids listed above.
The nuclear extracts were isolated and normalized to ensure equal
amounts of p53 protein in the gel shift assay. B: S116/127A but not
S116/127D binds to DNA: lanes 2 and 3 show DNA binding of pu-
ri¢ed baculovirus-expressed p53. Lanes 4 and 5 show DNA binding
of nuclear extracts from Saos2 cells transfected with an empty vec-
tor. Lanes 6^16 show DNA binding of nuclear extracts from wild-
type p53 and Saos2 cells transfected with various mutant p53.
           
Fig. 3. p53 S116/127D exhibits a structural mutant conformation.
Left panel: In vitro transcription and translated lysates were immu-
noprecipitated with Ab-5 (Pab1620) or Ab-3 (Pab240). Right panel:
Lysates from cells transfected with wild-type or mutant p53 were
immunoprecipitated with either Ab-5 (Pab1620) or Ab-3 (Pab240),
and p53 was detected with an anti-p53 polyclonal antibody follow-
ing immunoprecipitation.
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3.4. S116/127D is not resistant to Mdm2-mediated protein
degradation
The N-terminus of the p53 core DNA binding domain has
been implied in Mdm2-mediated protein degradation. Because
the S116/127D mutant exhibits the structural mutant confor-
mation, we examined whether this conformation would result
in a loss of p53 sensitivity to Mdm2-mediated protein degra-
dation. To test this, we ¢rst transfected the p53 S116/127D
mutant into p53 and Mdm2 double knockout MEF cells
(p533/3 ; Mdm23/3) and performed Western blotting. As
shown in Fig. 4A, the protein levels of S116/127D were com-
parable to that of the wild-type p53, which suggests that a
lack of Mdm2-mediated protein degradation plays a critical
role in S116/127D stabilization. Mdm2 has been shown to
interact with the N-terminal domain of p53, and this interac-
tion is not greatly a¡ected by point mutations in the p53
DNA binding domain [17]. To determine whether Mdm2
can a¡ect the protein stability of the inactive S116/127D mu-
tant, we cotransfected Mdm2 with wild-type p53 in the p533/
3 ; Mdm23/3 cells. Similar to results for the wild-type p53,
cotransfection of Mdm2 indeed leads to S116/127D, R175H
and R248W protein degradation (Fig. 4B). Similar results
have been observed in Saos2 cells (Fig. 4C). These results
suggest that the S116/127D mutant, although exhibiting the
structural mutant conformation, is not resistant to Mdm2-
mediated protein degradation.
Together, our results suggest that the serine residues 116
and 127 are important for p53 DNA binding and that the
substitution of the serine residues with aspartic acid leads to
a possible loss of p53-dependent transcription of Mdm2,
which results in a loss of protein degradation. Importantly,
we have shown that S116/127D exhibits a structural mutant
conformation. We consider the possibility that the simulta-
neous introduction of two large charged aspartate residues
into the compact core domain of p53 would result in its un-
folding. However, two lines of evidence suggest that this is
unlikely. First, the crystal structure of p53 reveals that Ser116
and 127 residues are either completely or partially on the
surface of the core domain. Second, similar to other p53 mu-
tants with the structural mutant conformation, the S116/127D
mutant can be degraded by the overexpression of Mdm2.
Notably, a recent study has suggested that COP9 signalosome
(CSN) phosphorylates p53 within the core domain of the pro-
tein (Thr155) and targets it to ubiquitin-mediated protein deg-
radation [11]. Mutation of Thr155 with valine (T155V) is suf-
¢cient to stabilize p53. Interestingly, the stabilized T155V
mutant also exhibits the structural mutant conformation
(Pab240+). Therefore, the alteration of charges in the core
domain, potentially through phosphorylation/dephosphoryla-
tion, could trigger a conformational change in the p53 mole-
cule and a¡ect its DNA binding and stability. Although we
have not yet obtained direct evidence of a phosphorylation at
Ser116 and 127 in vivo, our mutagenesis studies seemed to
support this notion.
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